These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19431095)

  • 1. Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer.
    Baron AT; Wilken JA; Haggstrom DE; Goodrich ST; Maihle NJ
    IDrugs; 2009 May; 12(5):302-8. PubMed ID: 19431095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.
    Baron AT; Cora EM; Lafky JM; Boardman CH; Buenafe MC; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):103-13. PubMed ID: 12582019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer.
    Müller V; Witzel I; Pantel K; Krenkel S; Lück HJ; Neumann R; Keller T; Dittmer J; Jänicke F; Thomssen C
    Anticancer Res; 2006; 26(2B):1479-87. PubMed ID: 16619561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole.
    Lafky JM; Baron AT; Cora EM; Hillman DW; Suman VJ; Perez EA; Ingle JN; Maihle NJ
    Cancer Res; 2005 Apr; 65(8):3059-62. PubMed ID: 15833834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
    Reid A; Vidal L; Shaw H; de Bono J
    Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C; Vidal L; Siu LL
    Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
    Hudelist G; Köstler WJ; Gschwantler-Kaulich D; Czerwenka K; Kubista E; Müller R; Helmy S; Manavi M; Zielinski CC; Singer CF
    Eur J Cancer; 2006 Jan; 42(2):186-92. PubMed ID: 16326100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
    Modjtahedi H; Essapen S
    Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib?
    Zampino MG; Magni E; Santoro L; Zorzino L; Dell'Orto P; Sonzogni A; Fazio N; Monfardini L; Chiappa A; Biffi R; de Braud F
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):139-48. PubMed ID: 18327586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of growth factor signalling.
    Wakeling AE
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S183-7. PubMed ID: 16113095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble epidermal growth factor receptor isoforms in non-small cell lung cancer tissue and in blood.
    Maramotti S; Paci M; Miccichè F; Ciarrocchi A; Cavazza A; De Bortoli M; Vaghi E; Formisano D; Canovi L; Sgarbi G; Bongarzone I
    Lung Cancer; 2012 Jun; 76(3):332-8. PubMed ID: 22177532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.
    Lafky JM; Wilken JA; Baron AT; Maihle NJ
    Biochim Biophys Acta; 2008 Apr; 1785(2):232-65. PubMed ID: 18291115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
    Crawford J
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T; Liu G; Tsao MS
    Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of HKI-272 and related compounds for the treatment of cancer.
    Wissner A; Mansour TS
    Arch Pharm (Weinheim); 2008 Aug; 341(8):465-77. PubMed ID: 18493974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing the efficacy of hormonal agents with selected targeted agents.
    Johnston SR
    Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S28-36. PubMed ID: 19561004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells.
    Grunt TW; Wagner R; Grusch M; Berger W; Singer CF; Marian B; Zielinski CC; Lupu R
    Biochem Biophys Res Commun; 2009 Jul; 385(3):454-9. PubMed ID: 19467222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary Evidence on the Diagnostic and Molecular Role of Circulating Soluble EGFR in Non-Small Cell Lung Cancer.
    Lococo F; Paci M; Rapicetta C; Rossi T; Sancisi V; Braglia L; Cavuto S; Bisagni A; Bongarzone I; Noonan DM; Albini A; Maramotti S
    Int J Mol Sci; 2015 Aug; 16(8):19612-30. PubMed ID: 26295387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble epidermal growth factor receptor acridinium-linked immunosorbent assay.
    Lafky JM; Baron AT; Maihle NJ
    Methods Mol Biol; 2006; 327():39-47. PubMed ID: 16780211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.